Morgans suspects the broader IVF market is stabilising, as recovery in NSW and Victoria offsets weakness in Queensland.
The weakness in the Virtus Health share price is considered an opportunity, seemingly affected by the unexpected downgrade by Monash IVF ((MVF)). The broker notes that the Monash issues are independent of the broader market.
Morgans upgrades to Add from Hold. Target is $5.46.
Sector: Health Care Equipment & Services.
Target price is $5.46.Current Price is $5.04. Difference: $0.42 – (brackets indicate current price is over target). If VRT meets the Morgans target it will return approximately 8% (excluding dividends, fees and charges – negative figures indicate an expected loss).